We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two Bespoke CAR-T Regimens Shine for Refractory B-Cell Lymphoma
Two Bespoke CAR-T Regimens Shine for Refractory B-Cell Lymphoma
Two CAR-T treatments — one from Gilead Sciences and another from Bristol Myers Squibb (BMS) — trounced standard-of-care as second-line therapies for patients with relapsed or refractory large B-cell lymphomas in two late-stage studies.